<DOC>
	<DOCNO>NCT00703560</DOCNO>
	<brief_summary>The purpose study evaluate happen hepatitis C virus response treatment pegylated interferon ribavirin patient HCV compare HIV HCV . This research do help u identify composition HCV change interferon different population . We examine quickly HCV clear body factor may influence clearance . This information may help u find good treatment HCV .</brief_summary>
	<brief_title>Study Hepatitis C Virus ( HCV ) Viral Kinetics HIV/HCV HCV Patients</brief_title>
	<detailed_description>All patient participate study frequent blood drawn order measure quickly HCV virus decline . Pegylated interferon ribavirin provide study , obtain part standard care treatment hepatitis C. Participants must willing spend 48 hour hospital frequent blood draw . They compensate time . All patient must HCV genotype 1 . All patient must liver biopsy prior enrollment study . ( This provide study ) . HIV-infected patient must CD4 cell count &gt; 300 . If HIV-infected antiretroviral therapy HIV , must stable regimen 12 week . The HIV regimen include didanosine ( Videx ) .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>1 . HCV infection , document presence circulating level HCV RNA RTPCR bDNA assay perform laboratory CLIA certification equivalent within 52 week prior study entry . 2 . HCV RNA &gt; 1000 IU/ml . 3 . Documented genotype 1 perform CLIA certify lab . 4 . Men woman age 18 65 year . 5 . Ability willingness subject legal guardian/representative give write informed consent . 6 . Female study volunteer reproductive potential must willing use two method birth control order prevent pregnancy IFN/RBV . For HIV infect patient : 1 . HIV1 infection , document licensed ELISA test kit confirm Western blot time prior study entry . HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA acceptable alternative confirmatory test . 2 . CD4+ cell count ³ 300 cells/mm3 within prior 12 week CLIA certify lab equivalent . 3 . Subject may HAART naïve , HAART stable regimen 12 week The HAART regimen include didanosine ( Videx ) . Interaction ribavirin didanosine lead fatal hyperlactatemia patient . 1 . Unwilling admit 48 hour serial blood draw virology study . 2 . Hepatitis B surface antigen ( HBsAg ) positivity . 3 . Prior IFN base therapy . Additional Exclusion HIVinfected : 1 . Current symptomatic HIV disease ( i.e. , AIDSdefining illnesses ) . 2 . HAART regimen contain Videx ( Didanosine ) . Subject may previously didanosine new HAART regimen regimen 12 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HCV</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>HIV co-infection</keyword>
	<keyword>viral kinetics</keyword>
	<keyword>HCV quasi-species</keyword>
	<keyword>Hepatitis C genotype 1</keyword>
	<keyword>HIV Infections</keyword>
</DOC>